Showing results (591-600 of 727) with videos related to
Sort By:
Pageof 73
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibJustin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung CancerIbiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.Cancer Medicine|March 11, 2015
Complex renal cysts associated with crizotinib treatmentPatrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.The Science of the Total Environment|June 1, 2019
A baseline of atmospheric greenhouse gases for prospective UK shale gas sitesJacob T Shaw, Grant Allen, Joseph Pitt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.ACS Medicinal Chemistry Letters|March 28, 2015
Synthesis and Evaluation of Quinazolines as Inhibitors of the Bacterial Cell Division Protein FtsZGabriella M Nepomuceno, Katie M Chan, Valerie Huynh, et al.Frontiers in Oncology|July 11, 2025
Young lung cancer: from diagnosis to survivorshipNarjust Florez, Lauren Kiel, Rebekah Kaufman, et al.The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.The Journal of Infection|September 5, 2001
Antiretroviral therapy for HIV-2 infected patientsN A Smith, T Shaw, N Berry, et al.Pageof 73